<DOC>
	<DOCNO>NCT00066703</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use triptorelin , exemestane , tamoxifen may fight breast cancer block use estrogen . It yet know whether give triptorelin together exemestane effective triptorelin tamoxifen treat hormone-responsive breast cancer . PURPOSE : This randomized phase III trial study triptorelin exemestane see well work compare triptorelin tamoxifen treat premenopausal woman hormone-responsive breast cancer .</brief_summary>
	<brief_title>Triptorelin With Either Exemestane Tamoxifen Treating Premenopausal Women With Hormone-Responsive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free survival , breast cancer-free interval , distant recurrence-free interval overall survival premenopausal woman endocrine-responsive breast cancer treat triptorelin exemestane v triptorelin tamoxifen . - Compare quality life , include late side effect early menopause , patient treat regimen . OUTLINE : This randomized , international , multicenter study . Patients stratify accord plan use concurrent adjuvant chemotherapy ( yes v ) , number positive lymph node ( 0 vs 1 ) . Treatment duration 5 year . Patients follow every 3 month 1 year , every 6 month 5 year , annually thereafter . Quality life assess baseline , every 6 month 2 year , annually 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Completely resect disease No clinically detectable residual locoregional axillary disease Prior surgery primary breast cancer 1 follow type : Total mastectomy without adjuvant radiotherapy Breastconserving procedure ( e.g. , lumpectomy , quadrantectomy , partial mastectomy margin negative* invasive disease ductal carcinoma situ ) plan radiotherapy NOTE : *If margin clear positive posterior ( deep ) margin permit , provide excision perform pectoral fascia tumor remove OR positive anterior ( superficial ; abut skin ) margin allow provided tumor remove Tumor confine breast axillary node Tumor detect internal mammary chain node sentinel node procedure enlarge allow Axillary lymph node dissection negative axillary sentinel node biopsy require Patients negative microscopically positive axillary sentinel node eligible Positive sentinel node must either axillary dissection radiation axillary nod No distant metastases No locally advance inoperable breast cancer , include follow : Inflammatory breast cancer Supraclavicular node involvement Enlarged internal mammary node ( unless pathologically negative ) Bilateral synchronous invasive breast cancer allow disease meet eligibility criteria No prior ipsilateral contralateral invasive breast cancer Hormone receptor status : Estrogen and/or progesterone receptor positive At least 10 % tumor cell positive immunohistochemistry If &gt; 1 breast tumor , tumor must hormone receptor positive PATIENT CHARACTERISTICS : Age Premenopausal Sex Female Menopausal status Premenopausal Estradiol premenopausal range prior surgery OR meet follow criterion : Menstruating regularly past 6 month Has use form hormonal treatment ( include hormonal contraception ) within past 6 month Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic No systemic hepatic disease would preclude prolonged followup Renal No systemic renal disease would preclude prolonged followup Cardiovascular No systemic cardiovascular disease would preclude prolonged followup No prior thrombosis ( e.g. , deep vein thrombosis ) and/or embolism unless patient medically suitable Pulmonary No systemic pulmonary disease would preclude prolonged followup Other Not pregnant nursing Fertile patient must use effective nonhormonal contraception No history noncompliance medical regimens No nonmalignant systemic disease would preclude prolonged followup No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , nonbreast carcinoma situ , contralateral ipsilateral carcinoma situ breast , nonrecurrent invasive nonbreast malignancy , include follow : Stage I papillary thyroid cancer Stage IA carcinoma cervix Stage IA B endometrioid endometrial cancer Borderline stage I ovarian cancer No psychiatric , addictive , disorder would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Prior concurrent neoadjuvant adjuvant trastuzumab allow Chemotherapy No prior neoadjuvant adjuvant chemotherapy Endocrine therapy No prior tamoxifen , selective estrogenreceptor modulators ( SERMs ) ( e.g. , raloxifene ) , hormone replacement therapy 1 year breast cancer diagnosis No prior neoadjuvant adjuvant endocrine therapy since diagnosis breast cancer No concurrent oral transdermal hormonal therapy No concurrent estrogen , progesterone , androgens No concurrent aromatase inhibitor No concurrent oral hormonal contraceptive ( i.e. , implant depot injection ) Radiotherapy See Disease Characteristics No prior ovarian radiotherapy Surgery See Disease Characteristics No prior bilateral oophorectomy Other No concurrent bisphosphonates , except follow case : Bone density least 1.5 standard deviation young adult normal mean Participation randomize clinical study test bisphosphonates adjuvant breast cancer set No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
</DOC>